| Trial ID: | L2186 |
| Source ID: | NCT02637973
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
|
| Acronym: |
EmLiFa
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Non-alcoholic Fatty Liver Disease
|
| Interventions: |
DRUG: Empagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in liver fat content, Change in liver fat content between baseline and 24 weeks measured with magnetic resonance spectroscopy, from baseline to 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: The Deutsche Diabetes Forschungsgesellschaft e.V. | Collaborators: Boehringer Ingelheim
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
84
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-12
|
| Completion Date: |
2018-08
|
| Results First Posted: |
|
| Last Update Posted: |
2023-06-05
|
| Locations: |
Charite Universitaetsmedizin Berlin, Berlin, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, 01307, Germany|German Diabetes Center, Dusseldorf, Germany|University Clinic Heidelberg, Heidelberg, Germany|University Clinic Tübingen, Tübingen, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT02637973
|
